At a glance
ClinicalIndex Comparison Record- ✓Age 21-50 years
- ✓Social drinkers consuming 1-6 standard drinks per week with ≤5 binge episodes in past year
- ✓BMI 19-30
- ✓Able to read English at 6th grade level and complete study evaluations
- ✕Current DSM-V alcohol or substance abuse/dependence (except nicotine)
- ✕Positive drug screen after intake for opiates, cocaine, marijuana, benzodiazepines, or barbiturates
- ✕Regular use of psychoactive drugs including anxiolytics and antidepressants
- ✕Psychotic or severely psychiatrically disabled
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers
In Brief
A Phase 1 clinical trial evaluating Saracatinib for Alcohol Drinking. Completed, enrolled 5 participants across 1 site.
Detailed Summary
The purpose of this alcohol-interaction pilot study is to provide information on the effect of AZD0530 (Saracatinib) on the pharmacokinetics of alcohol and on alcohol responses, including stimulation, sedation, intoxication, body sway and physiological responses. The investigators propose to test the effects of a single dose of AZD0530 (125 mg) on alcohol related responses. This is a within subjects open label study in which the investigators plan to run 8 subjects to obtain 5 completers.
Study Details
Timeline
Interventions
Subjects will receive 125 mg Saracatinib for 8-11 days followed by an alcohol interaction lab session